vimarsana.com

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) who switched from prednisone to EMFLAZA® (deflazacort) following the FDA approval. The primary reason the majority of patients chose to switch to EMFLAZA was a desire to delay disease progression to improve the benefit and tolerability. During the 6-months average follow-up after switching, physician-reported outcomes were consistent with EMFLAZA addressing the primary reasons for switching. Data were presented at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical and Scientific Conference.

Related Keywords

,Duchenne Muscular Dystrophy ,Ptc Therapeutics ,Muscular Dystrophy Association ,Slow Disease Progression ,Corticosteroids ,Becker Muscular Dystrophy ,Muscular Dystrophy ,Prednisone ,ட சிகிச்சை ,தசை டிஸ்ட்ரோபி சங்கம் ,மெதுவாக நோய் ப்ரோக்ரெஶந் ,பெக்கர் தசை டிஸ்ட்ரோபி ,தசை டிஸ்ட்ரோபி ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.